PTAB rejects IPR challenges to Gilead patents

14-06-2018

PTAB rejects IPR challenges to Gilead patents

Hailshadow / iStockphoto.com

The Patent Trial and Appeal Board (PTAB) has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.


Initiative for Medicines, Access & Knowledge, I-MAK, patent, Sovaldi, Gilead, generics, hepatitis C, pharmaceuticals, PTAB

LSIPR